Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC

Clinical trial NCT03910712 · UNKNOWN

Trial details

NCT number: NCT03910712
Sponsor: Peking Union Medical College Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Breast Cancer Female HER2-positive Breast Cancer Hormone Receptor Positive Malignant Neoplasm of Breast Metastatic Breast Cancer Breast Diseases Hormone Receptor Positive Tumor

Start date: 2019-06-01
Primary completion: 2022-06-01
Enrollment: 250

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.